Kura Oncology, Inc.
Kura Oncology, Inc. (KURA) Revenue
Annual & quarterly revenue history · segment & region breakdown
KURA · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsKura Oncology, Inc. trailing twelve-month (TTM) revenue is $0.07B, an increase of 25.24% year-over-year from $0.07B in FY2025.
Revenue trend
2025 – 2008 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.07B | +$0.01B | +25.24% |
| 2024-12-31 | $0.05B | +$0.05B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare KURA revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Kura Oncology, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Kura Oncology, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Kura Oncology, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
KURA revenue · 4 questionsKURA's trailing twelve-month (TTM) revenue is $0.07B. That is an increase of 25.24% year-over-year from $0.07B in FY2025.
▸ Source: FMP · Kura Oncology, Inc. SEC filings · GAAP · Kura Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026